SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma receives US FDA nod for hyperactivity drug

02 Sep 2010 Evaluate

Sun Pharma’s subsidiary has received abbreviated new drug application approval from the US Food and Drug Administration to market generic atomoxetine hydrochloride capsules in strengths of 10 mg ,18 mg ,25 mg, 40 mg, 60 mg and 100 mg.The company has received 180 days marketing exclusivity for these atomoxetine hydrochloride capsules. 

Atomoxetine hydrochloride capsules are indicated in the treatment of attention deficit hyperactivity disorder.The generic atomoxetine capsules are equivalent to Eli Lilly's strattera capsules and the annual sales of both branded and generics is estimated to be over USD 530 million in the US market. 

crackcrack

Sun Pharma Inds. Share Price

1668.00 -7.20 (-0.43%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×